Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
The story makes clear the “big unknown” remains the price and “how much people are willing to spend to cut a day or so off of a bout of flu.” The story reports that Genentech, the drug’s manufacturer, said it’s too early to comment on the drug’s U.S. price. The story also notes that in Japan, where the drug was invented, it “sells for the equivalent of about $43.50.” The story uses terms like “a little more than a day” and “nearly a day” and “substantially” to describe the drug’s reduction in flu symptoms, fever, and coughing and sneezing, respectively. It does not explain, as the news release does, that: “Similar efficacy results were seen between baloxavir marboxil and [Tamiflu] in relation to duration of symptoms and fever reduction.” In other words, on the symptom front, both drugs were the same. According to the news release, a difference was seen in the length of time the virus was shed from the body (presumably through coughing and sneezing): 24 hours for baloxavir marboxil verses 72 hours for Tamiflu. The news release also states that there was also a difference seen in the level of virus in the nose and throat, but it provides no precise numbers. It is not known whether this benefit translates into less infection transmission, and the story should have made that clear. The news release issued by Genentech about the FDA’s decision to grant priority review describes baloxavir marboxil’s most common side effects: diarrhea, bronchitis, nausea and sinusitis. The news release also states that overall incidence of adverse events seen in patients taking baloxavir marboxil were lower than those seen in both the placebo group and the group taking Tamiflu. The STAT News story does not mention any potential harms. This evidence comes from the randomized phase III Capstone-1 study the FDA will review, which included 1,436 people in the US and Japan. It excluded people older than 64. The news story does not note this exclusion, nor does it state a key problem with this study: It has never been published in a peer-reviewed journal (instead, a study abstract was released as part of ID Week 2017). This means the full data analysis has never been seen by anyone other than the researchers. We explained why this is important in February 2018, when we discussed news coverage of the drug’s approval in Japan. The 2017-2018 flu season was the worst the US had experienced in nearly a decade. The flu impacted the entire country, and was responsible for 172 pediatric deaths. The news article did not use these or any other flu-related statistics to increase fear about the flu and, in turn, the need for this medication. The article includes two sources: Mark Eisner, Genentech’s VP of product development for immunology, infectious diseases and ophthalmology and Richard Webby, head of the World Health Organization’s influenza collaborating center at St. Jude Children’s Research Hospital in Memphis. Eisner’s affiliation with Genentech, the drug’s manufacturer, is clearly noted. Webby does not appear to have any conflicts of interest. The article would have been stronger if it had included a third source who commented on what–if anything–is known about whether reducing the duration of symptoms leads to reduced levels of transmission that result in fewer people contracting the flu and fewer deaths. The story explains that the only other drug approved to treat the flu is Tamiflu, which is not widely used. The writer explains that both drugs need to be taken within 48 hours of symptom onset and that baloxavir marboxil is a single one-time dose, while Tamiflu must be taken twice daily for five days. It is clear from the story that the FDA is expected to decide by the end of the year whether to approve this new flu medication. The story explains that it’s been more than 20 years since a new class of flu drug has been developed and marketed. (It is available in Japan.) The catalyst for the story was a news release issued by Genentech about the FDA granting priority review of baloxavir marboxil, but the story does not use direct quotes from the news release.

Ex Output:
A flu drug — shown to reduce the duration of symptoms — could upend treatment in U.S.


Ex Input:
Montreal Canadiens Max Pacioretty lies on the ice after being hit into a glass stanchion by Boston Bruins Zdeno Chara during the second period of NHL hockey play in Montreal, March 8, 2011. REUTERS/Shaun Best With the National Hockey League playoffs under way after a season where jarring head shots grabbed headlines, researchers said the number of concussions was leveling off. But the ice time a player loses more than doubles with each subsequent concussion, so there were more absences. “Either concussions are becoming more severe or physicians are becoming more conservative with their management decisions,” said Brian Benson, a physician at the University of Calgary’s faculty of kinesiology and the lead author of the report. “We’re uncertain of the exact reason but it’s certainly an observation of the study.”   The report now goes to the NHL’s concussion working group, which will examine ways to prevent concussions, or work out how to respond when they do happen. “The goal in hockey in general is to reduce the risk of this potentially devastating injury without necessarily changing the nature of the game that millions love and enjoy watching,” Benson said. “You don’t want to make haphazard decisions but you certainly want to base it on evidence and try to reduce this foreseeable, predictable risk.”   The league has faced many calls for tougher penalties for potentially career-ending hits to the head, including some this season after a March incident in which Max Pacioretty of the Montreal Canadiens was injured after a body check that sent his head into a stanchion. He suffered a concussion and fractured vertebra. Sidney Crosby, Canada’s gold-medal goal-scorer in the 2010 Winter Olympics, has been off the ice since suffering a concussion in January. The researchers worked with the NHL and NHL Players’ Association to analyze 559 doctors’ reports of concussions suffered by players between 1997 and 2004. Their findings are published in the Canadian Medical Association Journal. The researchers estimated that there were 1.8 concussions per 1,000 player hours, a number that leveled off through the study period. The most-often reported symptom was headache at 71 percent. But players also reported dizziness, nausea, neck pain, fatigue, blurred vision or amnesia. Some 18 percent lost consciousness. For each recurrent concussion, the typical number of days lost increased by 2.25 times. Benson has worked with the NHL and its players union since 1997 studying the medical science behind brain injury.

Ex Output:
Concussions keep hockey players off ice for longer.


Ex Input:
In 1976, U.S. President Gerald Ford signed off on the National Emergencies Act (NEA), federal legislation that ended all previous national states of emergency and formalized the process by which the President can declare states of emergencies and undertake special powers during those emergencies. In general, the President may initiate a state of emergency by issuing a declaration (typically via executive order). An existing state of emergency can be terminated by the President himself, or by a joint resolution by Congress. The President can veto such a resolution, however, requiring both houses of Congress to then override the veto by a two-thirds vote. When President Donald Trump hinted in early 2019 his intention to bypass Congress and secure funding for building a wall along the U.S.-Mexico border by declaring a national emergency — and then followed through on that plan — the subject of “national emergencies” suddenly became a hot topic of public discussion. Since the public tends to associate that term with dire threats such as terrorist attacks, epidemics, or the outbreak of war, many people were surprised to learn that several dozen national emergencies had been declared since the passage of the NEA in 1976 — as reflected in a viral social media post:  According to the Brennan Center for Justice, at the time of President Trump’s declaration of a National Emergency Concerning the Southern Border of the United States in February 2019, some 58 national emergencies had previously been declared by various presidents since 1979, with 31 of them still in effect as of February 2019. The gist of the social media post displayed above is therefore correct, in that every U.S. president since 1976 (excluding Gerald Ford, whose term ended in January 1977) has declared at least one national emergency, although we came up with some slightly different numbers. (Our tally based on the Brennan Center’s list has Presidents George H.W. Bush and George W. Bush each declaring one more emergency than stated above, and President Barack Obama declaring one fewer than stated.) In addition, the majority of those emergency declarations remain in effect as of this writing. The focus of these national emergencies has ranged from President Carter’s blocking Iranian government property after fifty-two American diplomats and citizens were taken hostage in Tehran in 1979 and President Reagan’s barring trade with Nicaragua in 1985, to President Clinton’s prohibiting transactions with terrorists who threatened to disrupt the Middle East peace process in 1995 and President Obama’s declaring an emergency over the H1N1 influenza pandemic of 2009.

Ex Output:

Every U.S. president since 1976 has declared at least one national emergency.